The Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) drugs in development market research report provides comprehensive information on the therapeutics under development for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) and features dormant and discontinued products.
GlobalData tracks six drugs in development for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) by six companies/universities/institutes. The top development phase for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) is preclinical with four drugs in that stage. The Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline has five drugs in development by companies and one by universities/ institutes. Some of the companies in the Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline products market are: Scynexis, University of Pittsburgh and 60 Degrees Pharmaceuticals.
The key targets in the Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline products market include 1,3 Beta Glucan Synthase (EC 2.4.1.34), DNA, and Protein Tyrosine Phosphatase (EC 3.1.3.48).
The key mechanisms of action in the Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline product include 1,3 Beta Glucan Synthase (EC 2.4.1.34) Inhibitor with two drugs in Phase III. The Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline products include six routes of administration with the top ROA being Intravenous and two key molecule types in the Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline products market including Small Molecule, and Recombinant Vector Vaccine.
Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) overview
Pneumocystis pneumonia (PCP) is an infectious lung disease caused by Pneumocystis jirovecii fungi. A compromised immune system is the main risk factor for PCP. Sudden fever, cough, trouble breathing, chest tightness, and weight loss are the symptoms of PCP. The diagnostic tests include chest X-ray, blood tests, sputum culture, and bronchoscopy. The most common drug used for preventing and treating PCP is co-trimoxazole (trimethoprim and sulfamethoxazole).
For a complete picture of Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
